StemCell Therapy

Aley: We don't see uncertainty denting demand

Pension risk transfer volumes this year will look similar to those in 2020 as market volatility creates opportunities for schemes able to act fast, according to Willis Towers Watson.

In its annual de-risking report, published today (19 January), the consultancy predicted that buy-in and buyout volumes would top 30bn in 2021, while longevity swap deals would approach 25bn.

Around 24.2bn of bulk annuity deals for 2020 have so far been announced, although Willis Towers Watson said it was aware of at least 26bn announced or that it had advised on, while another 4bn are set to be confirmed within the coming weeks.

Willis Towers Watson said market volatility seen in 2020, which led to "incredibly attractive" insurer pricing as credit spreads widened, could be repeated in 2021 amid continuing pressures from the pandemic and Brexit.

On a similar note, lower than expected rates of mortality improvement in the years to 2020, as well as a growth in the number of reinsures in the market, has contributed to reduced costs of pensioner longevity swap pricing, a trend the consultancy expected to continue.

Managing director in transactions Ian Aley commented: "The pensions de-risking market has proved itself to be incredibly resilient and, while uncertainty will remain in 2021, we don't see this denting the desire and ability for pension schemes to complete risk management transactions.

"It remains to be seen what impact Covid-19 will have on longer-term expectations for mortality rates. For many schemes, the market pricing of longevity will currently look very attractive relative to their funding reserves.

"We therefore expect schemes will continue to look to lock into assumptions which are affordable against their current funding target to reduce future uncertainty as part of their wider hedging programmes."

Willis Towers Watson also predicted an "acceleration" in the superfund or defined benefit consolidation market following the introduction of an interim regulatory regime last year, particularly as Covid-19 financial support unwinds and corporates enter distressed scenarios.

Originally posted here:
Exclusive: Market volatility to spur 30bn of buy-ins and buyouts in 2021 - http://www.professionalpensions.com

A new health book is expected to reveal evidence supporting that Greek Australians are among those living longest lives on the planet.

Author Dr Norman Swan brought up the example speaking about the upcoming publication to 9 Channels Today show.

I started writing this book for millennials because they have a lot of questions to ask about their health[] theyre really interested in nutrition, Dr Swan said before revealing that first generation Greek Australians are the second longest lived people in the world after the Japanese.

But he says the reasons go beyond the benefits of the Mediterranean diet, speaking of a package of stuff.

They have their own herb garden and vegetable garden, theyre cooking fresh and cooking turns out to be really important because its a chemistry set to actually make you fell healthier.

READ MORE: Foraging Greek grandparents gardens for good health

Religion also plays a role, he contends in influencing diet.

What elderly Greek Australians do is they fast about a 100 days a year, but its a vegan fast no meat, or eggs, or dairy and they do live a long time.

Marketed as the ultimate health guide from Australias most trusted doctor, his upcoming book covers a wide range of health topics including nutrition and sex, with the aim of debunking common myths and making it easier for people to lead a healthy living.

Our minds have been filled with things to worry about from insomnia, to screen addiction, to guilt about not eating a paleo diet, to when will my eggs clap out and when will his sperm, to what really can make us live longer better? My aim is to get you to worry less and give you the information thatll allow you to make sensible decisions, whether youre 25 or 75, the author promises.

Dr Swan is a doctor and award-winning journalist with nearly four decades of experience in reporting medical news in Australia.

In the past year, his voice became familiar to millions as the host of the ABCs Coronacast, a podcast breaking down latest news and research on the novel coronavirus, reaching up to 3 million downloads monthly.

READ MORE: Adding life to years: Cooking in Ikaria, the Greek island of longevity

Read more here:
Greek Australians have second highest longevity in the world, says Dr Norman Swan - Neos Kosmos

Chris Horsley explores the longevity of thermal fluid heaters

For a process heating equipment manufacturer, you might just say thermal fluid heaters are bad for business.They just go on and on and on, and maintenance and service requirements are low, in fact a fraction of the cost of maintaining an equivalent heat output steam plant.Wheres the repeat business?Wheres the big service contracts and money to be made replacing worn parts?Of course, for a customer, this is music to your ears!

Thermal fluid heaters frequently run for 20 years and often longer.Even when the heaters themselves might be at the end of their working life, the pipe work system and other plant is often as good as new, so upgrades are simple and cost effective to implement at any time.

Thermal fluid heating is based on a similar principle to a simple hot water system. It consists of a heater connected to carbon steel flow and return pipework that can provide heat to one or more users or systems.Instead of water running through the pipework, a thermal fluid typically a specialist mineral oil or synthetic based fluid is used as the heat transfer medium.Different fluids can be used to meet specific process heating requirements including high temperature operations and processes requiring heating and cooling thereby making it a very flexible system.

Thermal fluid heaters typically operate at up to 350C at atmospheric pressure and remain pumpable down to minus 20C and lower with special fluids, which makes it a solution suitable for a multitude of applications.

Thermal fluid heaters have rapidly grown in popularity across all industry sectors over the years.This is mainly due to their far-ranging benefits which include their ease of use, compact size, safer operation when compared to steam generators, precise heat control, low exhaust emissions and their energy efficiency.They also operate outside the Pressure Systems Safety Regulations as the fluid is not maintained in the liquid phase by pressure, so statutory inspections are eliminated.This further reduces operating costs and increases plant availability.

When it comes to flexibility in use, thermal fluid heaters often work at high temperatures in a simple closed loop.Compared to a steam system this means no change of state of the fluid, so no condensate and therefore no flash steam losses, no blow down losses or make up water required, no effluent discharge and completely corrosion free operation without the need for expensive chemical treatment.The savings thermal fluid heaters bring are very significant, often up to 50% of the overall cost of running a process heating system.

But one aspect that frequently gets overlooked is the longevity thermal fluid heaters enjoy, which should be a major point when deciding how to heat a process, especially in these uncertain times when many businesses are having to buckle belts that much tighter. With sustainability a key issue, plant longevity is not only about reducing capex, but also reducing wastage and equipment redundancy.

As mentioned, a thermal fluid system should easily serve you 20 or more years without any reduction in productivity as it ages.It would be difficult to find any equipment, process or otherwise, that can match this level of service.Take a car, for example.Assuming the car runs at an average 30mph and covers 200,000 miles before being scrapped it will operate for about 6000 hours in its total life.A Babcock Wanson thermal fluid heater, on the other hand, will usually run for more than 100,000 hours - or the equivalent of 3,000,000 miles with the minimum of service requirements! And thats just looking at heaters with a typical lifespan; Babcock Wanson is still servicing heaters that are more than 40 years old and working away every day quite happily!

Theres no secret elixir for long life when it comes to thermal fluid heaters.Their exceptional longevity is a direct result from their passive nature (there are very few moving parts) and the swapping out of water for a thermal fluid as the heat transfer medium.Unlike water and steam based systems, thermal fluid heaters are unaffected by corrosion caused by water over time, or by ambient temperature where water freezing within pipes leads to costly failures.In fact, most thermal fluids are mineral oil based so are effectively lubricants that help keep the system components protected in use.

However, not all thermal fluid heaters are equal, so it pays to do your homework.Heaters that will best stand the test of time are mostly designed for a downward fired configuration which ensures stress free and unrestricted expansion of the heater coils during normal operation.Also look for a heater that has been designed with a barrier between the hot combustion gases and the outer structure, as this will help provide long heater life as the higher pressure and cooler outer air helps prevent any escape of combustion gases as the plant ages over time.Babcock Wansons TPC and EPC range of thermal fluid heaters, for example, come with an integral, air-cooled outer case that provides this barrier, as well as acting as both a combustion air pre-heater/economiser.Lastly, ensure the heater is fully integrated and has a factory tested control system.

Another key factor is overall emissions. With higher process operating efficiency comes lower total emissions which provides savings in operating costs whilst being much better for the environment.

Its also vital that the thermal fluid heater you decide upon is correctly installed, commissioned and maintained.Thermal Fluid Systems - A Practical Guide for Safe Design, Operation and Maintenancefrom the Combustion Engineering Association (CEA) proffers excellent advice for designers, owners, managers and operators of new and existing thermal fluid heating systems to operate safe and efficient installations. It addresses system design considerations such as choice of fluid, heat source, expansion and deaeration, pumps and pipework, to installation and commissioning and operation and maintenance. Its important to understand how thermal fluid heaters work to ensure you get the most out of your investment, including long life.

With careful system design and careful choice of heater design a thermal fluid system will provide many years of trouble-free ownership, allowing the operator to concentrate on their process needs in the sure knowledge they are getting the best from their process heating investment.

Chris Horsley, is Process Engineering Director at Babcock Wanson

Link:
Longevity of thermal fluid heaters - Engineer Live

COVID-19 has shaken the entire world, causing far and wide social and monetary havoc all over. The most evident and distressing thing is the huge number of lives lost to the pandemic, yet it keeps taking more and more. As authorities keep on trying to wrestle with controlling the pandemic, the lasting effects from this deadly virus still cause irreparable damage to the livelihood of everyone.

Without a doubt, the financial slump is unusual for anything the economy has ever experienced. Over the initial three months of the pandemic, a huge case of joblessness was reported. As the pandemic spreads, a complete shutdown of the economy can be expected.

As agonizing as this scene has been for everyone, it has been particularly going after the older population. While seniors profit through the basic help given through retirement plans, the COVID-19 pandemic has presented uncommon difficulties for this gathering. The most harmful component has been the radically higher fatality for retirement-age people.

Heres how older people have faced higher levels of difficulty and displacement in the face of this pandemic and recession.

Since COVID-19 has affected all different areas of the world, it has gotten to the retirement and nursing homes as well; because of the pandemic related death in these institutions, older people are opting out of this life. Moreover, most nursing homes are not equipped well enough to deal with the pandemic and dont have enough resources available on hand.

People are choosing to stay home and quarantine with their family members instead of spending this difficult time at a care home. The elderly were locked away in senior living centers before this and didnt have any emotional support from the outside, so aging at home will increase interaction between the younger and older generations.

As there has been an increase in the number of deaths due to COVID-19 in nursing homes, this can prove to be a good thing as age segregation is not likely favored by most retirees.

The pandemic is also disrupting our entire lifestyles as we cant socialize or engage in any activities outside the confines of our home. A healthy amount of physical and social activities is responsible for healthy mental and physical health.

Due to being confined to our homes, studies have shown how loneliness is related to causing a decline in our health, leading to depression, heart diseases, and overall cognitive decline; this is especially hard on the older population and can decrease life expectancy.

Most new technology discoveries are meant to be endorsed by the younger generations. That said, the pandemic has caused most tech entrepreneurs to think about the needs of older people at home as well.

There has been a wave of innovation in the tech field, aimed specifically at the needs of the older generation. Telemedicine has made it possible for people to have appointments with their doctors virtually and keep their health in check.

For example, wearable health devices and diagnostic tests have been very helpful in checking blood pressure, heart rate, and other vital signs and have made it easier for baby boomers to combat the effects of this pandemic.

Its inevitable to spend all your time at home, stuck in one place, not allowed to go anywhere, and not re-evaluate the life choices you have made. Due to all this free time at hand, the older generation is opting for a healthier lifestyle. They are making the most of all the idle time they have on their hands.

It has proven that life is short, and we have to make the most of our limited time on this planet. This has caused a lot of people to reassess how they spend their time and explore new and exciting hobbies.

On the other hand, some senior citizens are also feeling closer to nature, religion, and spirituality. They have more time on their hands, so prayer times have increased and people are reflecting more on morality, happiness, and connectedness.

After the re-evaluation of your life choices, its almost impossible not to think about death and make an end of life plans. Older people have been shown a reminder that they are not going to live forever. This has caused them to kick-start, making retirement and aging life plans.

However, this might be a difficult topic for most of us; its a smart choice to analyze all the expenses needed for your after-care and end of life planning. Theres a lot of helpful material online.

As mentioned above, this pandemic has practically forced us to reassess our life choices; it has also stirred up a lot of mixed feelings about retirement plans in the older generation. In fact, both younger and older members of society have started saving up for when they retire.

Due to the major decline in our economy, it has been made clear that its important to cut out extra costs and expenses. Its also best to have a proper budget and savings dedicated to retirement. Moreover, one needs to work longer and smarter, to be prepared for difficult times. Companies have also adapted to remote working and schedules, so its easier for older people.

The pandemic has been responsible for causing intergenerational conflicts among different societies. Its also affected how people belonging to different ages are dealing with this abrupt change of lifestyles.

This has caused us to think about aging from a different perspective. This is because older people have experienced times like this much longer than the rest of us; it has forced us to see how older people are more resilient in times of crisis.

The pandemic has brought people together. This is because, in times of distress and uncertainty, we are reminded of how much we need to stick together. Coronavirus has also helped remove the gap between generations. Its brought everyone closer together, regardless of age, as we are all in this together.

Arslan Hassan is an electrical engineer with a passion for writing, designing, and anything tech-related. His educational background in the technical field has given him the edge to write on many topics.

See the original post:
How Covid-19 Has Changed Aging and Retirement - Longevity LIVE - Longevity LIVE

Grapefruit is a citrus fruit thats rich in the powerful antioxidant lycopene, revealed dietitian Juliette Kellow and nutritionist Dr Sarah Brewer.

Regularly eating red grapefruit, specifically, could reduce the amount of bad cholesterol in your body, they said.

Everyone should aim to eat a portion of citrus fruits every single day to increase their lifespan, they added.

Best known for containing vitamin C, which supports the immune system, citrus fruits do far more than just fight infections, they said in their book Eat Better Live Longer Understand What Your Body Needs To Stay Healthy.

They are linked tight everything from protection against heart disease and cancer to slowing down cataract development.

Grapefruit help to lower cholesterol levels. [They] come in pink, red, and blond varieties. Pink and red are rich in lycopene, a powerful antioxidant.

READ MORE:How to live longer: Five habits to adopt into your life to increase life expectancy

FOLLOW US ON GOOGLE NEWS

Source

Read the original:
How to live longer: Grapefruit could prevent cancer, protect the heart and boost longevity - TechnoCodex

Taylor Wilderecently spoke with WrestleZone Managing Editor Bill Pritchard about her return to wrestling and took some time to reflect on the opportunities afforded to womens wrestlers and how things are moving forward. The Knockouts Tag Team Championship Tournament will conclude this Saturday at Hard To Kill, and while we know both teams in the final match, Wildesaid she was also excited for the opportunity thatHavok and Nevaeh have with a potential title win.

Im excited to see Havok and Nevaeh. Nevaehs always been someone who has strengths in tag team wrestling and tag divisions havent really existed for women exclusively outside of IMPACT really, so its interesting to see the angle she takes because from what I know about her on the independents, [Nevaeh] and Havok are real talent enhancers and theyve really helped change the trajectory of womens wrestling on the independents. Im excited to see what they can do with up-and-comers and the staples of the company. I love seeing whats old is new again and whats new is old because its very reminiscent of when I was last there, Wilde explained, and the Knockouts had a very important role on the show. It feels like were getting closer and closer to where we were before the Hogan invasion. [laughs]

Wilde also added that the continued push and diversification of womens wrestling opens up more opportunities once talent steps out of the ring. Wilde pointed to how women used to be aged out of the ring in the past, but new roles and being introduced its an exciting prospect.

Itd be wonderful and it just adds to that diversification of the Knockouts and womens wrestling because thats what weve moved to. Were way out of the Divas era and these women have substance, characters, and adding diversification also adds to the longevity of a womens career whereas before, once you hit the 35-40 range, Wilde said, youre [at a new stage in life], you know, and its a really great time [now] for womens wrestling.

You have Madison Rayne and Renee Young, who have been doing the ringside commentary and the backstage interviews, as well as Gail Kim being an agent. All of these things are really new in the last 5-10 years, but its very inspirational and motivating for not only someone like myself, Wilde said, who is in their golden years as far as wrestling goes, but for all of the up-and-comers, their careers wont be stunted by the time they are 35 or 40. They have much more to look forward to.

Check out what Taylor has been up to onher podcast,Wilde On. Season 2 premieres on Wednesday with Trish Stratus as her first guest.

Read More: Yes, Nevaeh Is Heaven Spelled Backward, But Her Inspiration For It Is Heartwarming

Excerpt from:
Taylor Wilde Is Inspired By Renee Young And Gail Kim, Says Diversification Adds Longevity To Womens Careers - Wrestlezone

Thats right, the new generation 500 cannot be bought with an internal combustion engine. Instead its been completely reinvented with new underpinnings and a new look. As an urban car, on paper, the 500 is the perfect model for electrification, so lets find out if it stacks up.

Pretty much everything except for the name is new. Its the first Fiat Chrysler Automobiles model to be built from the ground up as an electric vehicle, so its perhaps unsurprising that it has led with its most iconic car.

That makes it wider and longer than the outgoing model, gets level-two autonomous driving features, a futuristic twist on the classic 500 styling, and two battery size choices with fast charging up to 85kW. Its also offered as both a hatchback and convertible.

Whats under the bonnet?

The powertrain is impressively compact to maximise space in the cabin. Under the bonnet, where an engine would typically live, is a power electronic bay, which incorporates various aspects of the powertrain such as the charger module and power inverter. Beneath it sits the electric drive module, which has the motor and differential. Its output is 115bhp (or 94bhp on the smaller battery version) and 220Nm of torque.

Beneath the cabin sits the battery pack, which is available in 42kWh or 23.7kWh capacities, providing up to 199 and 115 miles of range respectively. The smaller battery can charge at a maximum rate of 50kW, which takes 30 minutes to get to 80% of charge, while the larger one can take up to 85kW, which takes 35 minutes to reach 80%.

Whats it like to drive?

In previous generations, the 500s trump card has always been its style, and while it hasnt been bad to drive, its far from class leading. However, the new 500 feels like a massive step up. Electric powertrains suit city cars down to the ground and this Fiat is no different.

The electric motor doesnt quite have the immediate kick of acceleration of some EVs, but its much more sprightly than a petrol car when driving around town. Its comfortable, too, without suffering from the overly harsh ride some rivals struggle with.

The 500 could have been the worst car ever made and it would still sell by the boatload because Fiat absolutely nailed the retro-modern styling. This new model has seen the most dramatic change yet, because although its unmistakably a 500, its got an ultra-modern edge that would be well-suited to a concept car.

Despite being larger now, its retained the charming dinky proportions we know and love. It has a solid front grille with a prominent 500 logo that should be tacky but has been implemented in a classy way, while the ring light around the oval headlights is a simple, modern yet characterful touch.

Again, the interior feels like its moved up a level. This is partly because the starting price is higher, as is the case with all EVs, so they tend to get more premium materials and style to help justify it. However, while the Fiat doesnt necessarily feel more premium, gone is the clunky, fussy interior of old and in its place is a sleek minimalist dashboard.

It has a simplified oval instrument binnacle design, which is about the only similarity with its predecessor. Now, the centre console is simply a prominent screen on the dashboard where most features are controlled from, as well as a few physical buttons below for the air conditioning and gear selection.

Prices start at 22,495 for the hatchback. There are four trim levels on the hatchback, while the drop-top goes without the entry-level Action trim, which is only available with the smaller battery. Standard equipment includes rear parking sensors, 15-inch alloy wheels, halogen headlights, air conditioning and digital instruments. However, theres no infotainment screen you get a smartphone cradle instead.

Step up to Passion and you get the larger battery, cruise control, automatic air conditioning and a seven-inch infotainment screen with Apple CarPlay and Android Auto. After this, Icon models get a leather steering wheel, passive entry with a wearable key, 16-inch alloy wheels, and 10.25-inch infotainment screen with sat-nav.

Finally, the top-spec La Prima trim gets extensive extra equipment, including wireless phone charging, leather seats, 360-degree parking sensors, 17-inch alloy wheels, LED headlights and a six-speaker sound system.

Reinventing the Fiat 500 was a big ask. But you have to say fair play to the Italians, because they have managed to find everything thats loved about the previous 500 and packaged it up in a modern-looking car with a future-proof electric powertrain.

Theres now more substance to the 500s style, because its great to drive, more spacious and has ultra-low running costs too. Its safe to say this city cars reign of success is likely to continue for a good while yet.

See the original post here:
First Drive: The Fiat 500 EV proves this supermini's unrivalled longevity - Jersey Evening Post

An analysis of a large nationally representative longitudinal study by University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science report that starting tobacco products, including e-cigarettes, before the age of 18 is a major risk factor for people becoming daily cigarette smokers.

Reporting in the January 11, 2021 online edition of Pediatrics, researchers found that in 2014 people age 12 to 24 who used e-cigarettes were three times as likely to become daily cigarette smokers in the future. Among those who reported using a tobacco product, daily use increased with age through age 28. Daily cigarette smoking nearly doubled between 18 to 21 year olds (12 percent) and 25 to 28 year olds (21 percent).

This is the first paper that actually looks at progression to dependent cigarette smoking among young adults. In these data, e-cigarettes are a gateway for those who become daily cigarette smokers, said the studys first author, John P. Pierce, Ph.D., Professor Emeritus at Herbert Wertheim School of Public Health and Human Longevity Science and UC San Diego Moores Cancer Center. The start product has changed from cigarettes to e-cigarettes, but the end product has stayed the same. When users become dependent on nicotine, they are converting to cigarette smoking.

Researchers used data from the Population Assessment of Tobacco and Health (PATH) Study, a longitudinal study of tobacco use and its effect on the health of people in the United States. The PATH Study, undertaken by the National Institute on Drug Abuse (NIDA) and the FDA Center for Tobacco Products under contract to Westat, enrolled a nationally representative sample of 12 to 24 year olds between in 2013 and 2014 and re-interviewed them annually for four years to explore progression to daily use among experimenters of 12 tobacco products.

In the first year, 45 percent of study participants reported using at least one tobacco product in their lifetime. By the fourth year, as participants aged, 62 percent reported some tobacco experimentation. Among those who have ever experimented with tobacco, 73 percent had tried cigarettes and 72 percent had tried e-cigarettes. Further, more than half tried hookahs and cigarillos. Traditional cigars, filtered cigars, smokeless products, pipes and snus were each tried by more than10 percent of study participants.

The analyses revealed that, by year four, 12 percent of participants were using tobacco products daily half of whom became daily users after the first year. Seventy percent of daily users smoked cigarettes and most of them (63 percent) used cigarettes exclusively. Of those who smoked cigarettes and used another tobacco product, half vaped e-cigarettes on a non-daily basis.

Among the 17 percent of daily users who were vaping every day, almost half were also non-daily cigarette smokers. Further follow-up will determine whether these young daily tobacco users continue to use both products or whether they settle on a single product, said Pierce.

What were seeing is that the proportion who are daily e-cigarette users did not increase with age. Whereas with cigarettes the number of users jumps up rapidly with age, said Pierce. This rapid increase with age only occurred with cigarettes, not with any other tobacco products.

Less than 1 percent of study participants who experimented with just one tobacco product progressed to daily cigarette smoking. People who had tried five or more products increased their risk of becoming daily cigarette smokers by 15 percentage points.

Trying e-cigarettes and multiple other tobacco products before the age of 18 is also strongly associated with becoming daily cigarette smoking, said senior author Karen Messer, Ph.D., professor at UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and director of biostatics at UC San Diego Moores Cancer Center.

We know that e-cigarette use among high school seniors, most under the age of 18, increased from 38 percent in 2016 to 45 percent in 2019. These results suggest that recent rapid growth in adolescent e-cigarette use will lead to increased daily cigarette smoking among young adults in the United States, reversing decades of decline in cigarette smoking.

Co-authors include: Ruifeng Chen, Eric C. Leas, Martha M. White, Sheila Kealey, Matthew D. Stone, Tarik Benmarhnia, Dennis R. Trinidad and David R. Strong, all of UC San Diego.

This research was funded, in part, by the National Institutes of Health (1R01CA234539) and by the Tobacco-Related Disease Research Program of the University of California Office of the President (28IR-0066).

See the original post:
Youth using e-cigarettes 3 times as likely to become daily cigarette smokers - University of California

Older consumers are a benefit to the economy rather than a drain on resources, according to new research.

The over 50s will spend 63p in every 1 in the UK by 2040 rising from 54p in the 1 in 2018.

And the money is spent across the board rather than on specific goods and services,

However, think-tank the International Longevity Centre (ILC) believes the country could benefit even more if the government looked at lifting barriers to spending by older people.

The ILC reportMaximising the longevity dividendreveals spending by the over 50s has dominated the UK economy since 2013 and will rise over the coming decades, from 54% (319 billion) of total consumer spending in 2018 to 63% by 2040 (550 billion).

According to the report, lifting barriers to spending by the over 75s could add 2% (47 billion) to GDP a year by 2040 and supporting the over 50s to remain in the workforce could add an another 1.3% to GDP a year by 2040.

David Sinclair, Director of the ILC, said: As the population ages there are enormous economic opportunities, but these are currently being neglected.

There are enormous gains to be made by individual businesses and for the economy if we can unlock the spending and earning power of older adults.

But too many people face barriers to working and spending in later life issues like inaccessible high streets, poorly designed products, and age discriminatory attitudes require a serious response.

Weve become accustomed to hearing our ageing population talked about as a bad thing but the reality is it could be an opportunity.

However, we wont realise this longevity dividend through blind optimism about ageing. Instead, we need concerted action to tackle the barriers to spending and working in later life.

We need action to make sure our extra years are healthy years, we need accessible high streets and workplaces that are free from age discrimination and we need continued action to ensure that people have access to decent pensions in later life.

Realising the longevity dividend will require decisive action of the kind weve yet to see from either business or government. For all the talk of baby boomers dominating politics, weve yet to see a serious response to the opportunities and this needs to change.

Further related information and articles can be found following the links below

Read the original here:
Over 50s Spending Spree Boosts Economy By Billions - Money International

This contemporary, modern market research compilation is a systematic overview of the overall market status and structure prevalent in global Longevity Biotech market and their rampant implications upon holistic growth trajectory and further probabilities in the near future. The report is based on extensive primary and secondary research initiatives and the insights thus achieved have been stacked systematically aided by several graphs, tables and charts to encourage seamless comprehension. The report sheds ample light into both past and current developments to infer futuristic probabilities. Relevant understanding on market prognosis, trends, policy updates and current development statistics have all been highlighted in thorough detail for quick deductions and subsequent investment discretion by Orbis Pharma Reports.

Get sample copy of [emailprotected] https://www.orbispharmareports.com/sample-request/91311

Major Company Profiles operating in the Longevity Biotech Market:

JuvenescenceUnity BiotechNapa Therapeutics?Ltd.LyGenesisBuckJuvenescence LimitedInsilico MedicineMajor Types CoveredTherapyDrug

By the product type, the market is primarily split into

TherapyDrug

By the application, this report covers the following segments

agingregenerationthe diseases of aging

Browse the complete report @ https://www.orbispharmareports.com/2015-2027-global-longevity-biotech-industry-market-research-report-segment-by-player-type-application-marketing-channel-and-region/

Regional Overview:This versatile research report presentation on global Longevity Biotech market, presented by Orbis Pharma Reports has maintained highest parameters of research practices to unravel crucial details. Holistic geographical diversifications have been carefully analyzed and prominent growth centers have been categorically flagged to maintain uniform growth trends.Besides entailing region-specific details, country-wise detailing have also been included to encourage rapid decision making. For maximum reader discretion and subsequent investment decisions, this report on global Longevity Biotech market as assessed by Orbis Pharma Reports reveals Germany, France, Italy, UK as ideal growth hotspots, followed by American growth hubs such as Mexico, Brazil, US and Canada. MEA countries and APAC nations have also been thoroughly scanned to understand growth patterns, competition intensity as well as vendor activities across these growth points.

For Any Query on the Longevity Biotech Market: https://www.orbispharmareports.com/enquiry-before-buying/91311

Decoding Segment Specifications:The report by Orbis Pharma Reports on global Longevity Biotech market encourages complete stratification of the market in terms of segments to understand growth patterns. All prominent segments highlighted in the report have been assessed based on set parameters such as capital diversion, inventory management as well as utility diversification, besides exploring supply chain developments to understand segment potential in growth progression. Each of the segment identified has been assessed on the basis of various market parameters to explore growth projections and likelihood. The report is based on complete SWOT and PESTEL assessment, followed by PORTERs Five Forces assessment and evaluation of all DROT factors. These details are highly crucial to encourage appropriate investment decisions on the part of inquisitive readers and aspirational investors.Orbis Pharma Reports also sketches the prevalent competition landscape, isolating frontline players as well as their growth proficient business decisions. Based on these business decisions, this report helps investors to deliver lucrative business decisions.

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

Originally posted here:
Global Longevity Biotech Industry Market 2021 Insights Business Opportunities, Current Trends And Restraints Forecast 2027:Juvenescence, Unity...

Its ironic that people have never been this anxious and stressed in a world that has never seen so much comfort, technological, and medical advancement. As if the more artificial certainty we create for ourselves through medicine, perfectly coordinated schedules, and effortless processes thanks to technology, we have become more afraid of the uncertainty of life.

Acceptance of this uncertainty is the first step to easing stress and anxiety. After all, the unknown is such a massive part of our life whether we choose to acknowledge it or not. After that, we can try to ease stress and anxiety with other healthy habits. Reducing the amount of sugar and exercising more outside are two excellent ways of bringing more peace into our life.

There is another natural way to ease stress and anxiety a natural compound that has been around for thousands of years known as CBD.

Short for cannabinol, CBD is the second most predominant active ingredient in the cannabis plant. CBD is derived from the hemp plant, and as a result, it contains a low level of delta-9 tetrahydrocannabinol (THC). The latter is a considerable component of marijuana it is the reason users become high. However, in hemp-derived CBD, the THC level is less than 0.3 percent, so users are at no risk of becoming high or overdosing.

This is why the World Health Organization (WHO) has deemed CBD a safe, natural compound. Its low THC content is also the reason countries such as the US have legalized CBD. Although research on this natural compound is limited, researchers have noted the significant potential CBD has for a list of chronic and mental health issues such as diabetes, depression, insomnia, PTSD, and more.

Thanks to its positive attributes, some of the worlds top CBD oil brands have made this natural compound more accessible and safer to buy, whether online or in a brick-and-mortar store. CBD oil is easy to ingest. You can take it sublingually by placing a drop under your tongue for it to be absorbed quickly, or you can add it to anything from your morning smoothie, coffee, cereal, or salad dressing.

Chemical imbalances in our brain and hormone imbalance in the body are the leading causes of stress and anxiety once we face stressful situations, whether they are real or imagined. Treating stress and anxiety with CBD is possible and safe. The following are three ways CBD oil can help.

For those who are chronically stressed and anxious, taking something that will make you feel you have lost control isnt a good idea. This is why anxious people who take marijuana do not enjoy the experience. Its because the high THC content and the mind-altering effects it brings makes them feel more anxious and paranoid.

This is not an issue with CBD. Since this natural compound causes no mind-altering effects, you will not experience more anxiety and stress caused by the fear of getting high and losing control. Researchers have noted no harmful side effects of CBD, and unlike some medications, it is gentle on the organs. The only known side effects some CBD users have experienced include nausea, diarrhea, and vomiting.

Cortisol is a critical hormone that helps us determine whether we fight or flight during an emergency. But when you suffer from chronic stress and cortisol is released continuously in the body, it leads to adverse effects. High levels of cortisol lead to a weak immune system, weight gain, and chronic fatigue. All of these factors can cause more stress.

CBD can help ease stress by balancing cortisol levels in the body. When you take CBD oil, the cannabinoids interact with the receptors running through the body. Although researchers have yet to understand how CBD interacts with the receptors, they know that it can signal to them and trigger change. Here, the change comes as more balanced cortisol levels in the body.

CBD can also trigger the release of more serotonin and GABA in the mind and body. Serotonin is a critical neurotransmitter that infuses us with the sense of well-being we need to feel less anxious. Located in the brain region, GABA helps ease anxiety by signaling to the body to be more relaxed. In both cases, CBD can interact with the receptors to trigger changes and encourage the body to increase serotonin and GABA levels.

Stress and anxiety are part of life, but they do not need to rule our days. Healthily dealing with them is better than avoiding these negative traits, as we would be allowing them to become worse. When you feel overwhelmed, it is best to turn to someone you can trust. They will remind you that although you may feel like it, you are not alone. You can get through this.

Continue reading here:
3 Benefits Of CBD Oil To Manage Anxiety And Stress - Longevity LIVE - Longevity LIVE

Following the leaves, a given rhizome will produce one or more flowering stalks. These stalks (also roughened) are without leaves themselves: such a stalk is called a scape. (Another good example of a scape would be the stem of a daffodil.). Each scape will bear a single flower, all the way at the top. A football-shaped, green bud eventually will open up, allowing the flowers 15 or so exquisitely pink (sometimes white) tepals to spread open. The center of the flower bears a lot of stamens, often more than 100, and several pistils, with each pistil embedded in a flattened receptacle.

At maturity, the tepals have all fallen away, and the receptacle swells a bit into a conical shape, with very hard, spherical seeds embedded in its tissue. These seeds are amazing for their longevity, easily sprouting after 100 years of dormancy. Some reports indicate that they may still be good after several centuries.

The entire plant, in addition to the rhizomes, has been used since antiquity in central and eastern Asia, where it is native, in various ways. But it is the extraordinary blossoms that make this species so special: a plant that can resurrect itself from quiet mud into something resplendent and almost sacred.

By the way, the seeds will sprout if scarified, and sometimes the rhizomes are available for planting. Be aware that, if happy enough, this plant can be invasive.

Visit link:
Mystery Plant: Beautiful, magical and edible, this aquatic bloom has many uses - The Daily Progress

Shares of Aclaris Therapeutics Inc. ACRS, +192.35% skyrocketed more than 200% toward a 2 1/2-year high, on massive volume, in midday trading Tuesday, after the biopharmaceutical company announced "positive" data from a Phase 2a trial of its rheumatoid arthritis treatment. The stock shot up 211.1%, putting it on track for the highest close since July 2018, to pace all gainers on major U.S. exchanges. Trading volume soared to 79.7 million shares, compared with the full-day average of about 859,000 shares. The company said the Phase 2a multicenter trial was randomized, patient-blind, sponsor-unblinded and placebo-controlled, and the primary endpoint was safety and tolerability of ATI-450, an investigational oral MK2 inhibitor. In the trial, the company said ATI-450 as generally well tolerated, showed no serious adverse events and demonstrated durable clinical activity. Aclaris Chief Medical Officer David Gordon said he believes the data supports the hypothesis that MK2 inhibition is an important novel target for treating immuno-inflammatory diseases, and he looks forward to progressing ATI-450 to Phase 2b. The stock has soared more than four-fold (up 305.5%) over the past three months, while the iShares Nasdaq Biotechnology ETF IBB, +1.75% has rallied 19.4% and the S&P 500 SPX, +0.80% has gained 10.6%.

See the original post here:
Aclaris Therapeutics stock more than triples after 'positive' data on arthritis treatment trial - MarketWatch

DEAR DR. ROACH: I would like to know how to treat arthritis. I have been using Voltaren per my doctors orders, but it does not seem to be helping much. I have also been taking ibuprofen, but I am afraid of stomach bleeding. The arthritis is in my wrists and thumb. I can hardly open a doorknob or lift any small objects. Does turmeric help?

I would appreciate any advice you can give me. It is hard to do any cooking or housework using my hands. They ache and throb all day. M.V.

ANSWER: There are several different types of arthritis of the hand, and it sounds as though your doctor has made the diagnosis of osteoarthritis, which is the most common type. Rheumatoid arthritis and psoriatic arthritis are inflammatory varieties that require very different therapies. Blood testing and X-rays help separate the different types of arthritis from one another if your history and physical exam indicate the need.

If you have osteoarthritis, oral anti-inflammatory medicines like Voltaren or ibuprofen (but NEVER both taking two different NSAIDs orally adds only toxicity, not effectiveness) are common and often effective treatments. Voltaren is also available as a gel, and its OK to use both Voltaren gel and a different oral NSAID such as ibuprofen. The gel is poorly absorbed into the body and is very unlikely to have systemic side effects.

However, remember that exercise improves pain and function. One set of exercises specifically for hand arthritis from the Mayo Clinic can be found at tinyurl.com/mayo-hand.

You asked about turmeric. There are studies showing benefit for turmeric and it has little toxicity, so I think it is worth a try. Similarly, Boswellia supplements have shown benefit in some people with osteoarthritis.

DEAR DR. ROACH: I tested positive for COVID-19 about six weeks ago. I had very mild symptoms for about 24 hours. I lost my sense of taste and smell. My senses are slowly returning, but now I constantly have a strange taste in my mouth. I cant tell if its a metallic taste or not. Eating, drinking, chewing gum, brushing, etc., make it go away for 10 minutes. Is this COVID-related or something else? Will it go away? -- M.R.

ANSWER: While I cant answer with certainty, many people with COVID-19 have disturbances in taste and smell that take weeks or months to resolve. Based on my experience with these patients, I would guess your disturbance is most likely COVID-19 related, and is likely to go away in time.

Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu or send mail to 628 Virginia Dr., Orlando, FL 32803.

Read more here:
Arthritis treatment needed for pain in hands - Northeast Mississippi Daily Journal

Machine learning was shown to identify patients with rheumatoid arthritis (RA) who present an increased chance of achieving clinical response with sarilumab, with those selected also showing an inferior response to adalimumab, according to an abstract presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR).

In prior phase 3 trials comparing the interleukin 6 receptor (IL-6R) inhibitor sarilumab with placebo and the tumor necrosis factor (TNF-) inhibitor adalimumab, sarilumab appeared to provide superior efficacy for patients with moderate to severe RA. Although promising, the researchers of the abstract highlight that treatment of RA requires a more individualized approach to maximize efficacy and minimize risk of adverse events.

The characteristics of patients who are most likely to benefit from sarilumab treatment remain poorly understood, noted researchers.

Seeking to better identify the patients with RA who may best benefit from sarilumab treatment, the researchers applied machine learning to select from a predefined set of patient characteristics, which they hypothesized may help delineate the patients who could benefit most from either antiIL-6R or antiTNF- treatment.

Following their extraction of data from the sarilumab clinical development program, the researchers utilized a decision tree classification approach to build predictive models on ACR response criteria at week 24 in patients from the phase 3 MOBILITY trial, focusing on the 200-mg dose of sarilumab. They incorporated the Generalized, Unbiased, Interaction Detection and Estimation (GUIDE) algorithm, including 17 categorical and 25 continuous baseline variables as candidate predictors. These included protein biomarkers, disease activity scoring, and demographic data, added the researchers.

Endpoints used were ACR20, ACR50, and ACR70 at week 24, with the resulting rule validated through application on independent data sets from the following trials:

Assessing the end points used, it was found that the most successful GUIDE model was trained against the ACR20 response. From the 42 candidate predictor variables, the combined presence of anticitrullinated protein antibodies (ACPA) and C-reactive protein >12.3 mg/L was identified as a predictor of better treatment outcomes with sarilumab, with those patients identified as rule-positive.

These rule-positive patients, which ranged from 34% to 51% in the sarilumab groups across the 4 trials, were shown to have more severe disease and poorer prognostic factors at baseline. They also exhibited better outcomes than rule-negative patients for most end points assessed, except for patients with inadequate response to TNF inhibitors.

Notably, rule-positive patients had a better response to sarilumab but an inferior response to adalimumab, except for patients of the HAQ-Disability Index minimal clinically important difference end point.

If verified in prospective studies, this rule could facilitate treatment decision-making for patients with RA, concluded the researchers.

Reference

Rehberg M, Giegerich C, Praestgaard A, et al. Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Presented at: ACR Convergence 2020; November 5-9, 2020. Accessed January 15, 2021. 021. Abstract 2006. https://acrabstracts.org/abstract/identification-of-a-rule-to-predict-response-to-sarilumab-in-patients-with-rheumatoid-arthritis-using-machine-learning-and-clinical-trial-data/

The rest is here:
Machine Learning Shown to Identify Patient Response to Sarilumab in Rheumatoid Arthritis - AJMC.com Managed Markets Network

This article was originally published here

J Rheumatol. 2021 Jan 15:jrheum.201226. doi: 10.3899/jrheum.201226. Online ahead of print.

ABSTRACT

OBJECTIVE: Both erectile dysfunction (ED) and rheumatoid arthritis (RA) are associated with increased cardiovascular risk. It is unknown if these diagnoses are associated or if their combination confers additional cardiovascular risk. We aim to define the incidence of ED in RA, and determine if ED correlates with increased cardiovascular risk in RA.

METHODS: Medical information concerning RA, ED and cardiovascular diagnoses for men with RA (n=260) diagnosed in Olmsted county, Minnesota and age-matched male comparators was extracted from a comprehensive medical record system.

RESULTS: ED incidence was similar between the RA cohort and comparators (HR 0.80; 95% CI 0.55-1.16). In men with RA, ED diagnosis was associated with a trend toward an increase in peripheral arterial disease (HR 2.22; 95% CI 0.98-5.03) and a significantly decreased rate of myocardial infarction (HR 0.26; 95% CI 0.07-0.90), heart failure (HR 0.49; 95% CI 0.25-0.94) and death (HR 0.56; 95% CI 0.36-0.87). In men with RA and ED, phosphodiesterase-5 inhibitor use was associated with a decreased risk of death (HR 0.35; 95% CI 0.16-0.79), with a trending decreased risk of some cardiovascular diagnoses.

CONCLUSION: Incidence of ED was not statistically increased in RA. Although patients with both RA and ED had a similar overall cardiovascular risk to those with RA alone, men with both RA and ED had decreased risk of heart failure, myocardial infarction and death, as well as an increased risk of peripheral arterial disease. Further studies are needed to clarify these associations and their implications for pathogenesis and therapeutics.

PMID:33452166 | DOI:10.3899/jrheum.201226

Read the original post:
Erectile Dysfunction and Cardiovascular Risk in Men with Rheumatoid Arthritis: A Population- Based Cohort Study - DocWire News

Two arthritis drugs, tocilizumab and sarilumab, have re-emerged as possible treatment options for Covid-19 with the UK government recommending their use based on a new study. The use of arthritis drugs, especially tocilizumab, against coronavirus has been the subject of debate through the pandemic, emerging as a choice at times and falling out of favour at other times. The latest study, which is on a preprint server (which means that it is yet to be peer-reviewed), its results unlike those of previous trials suggest that tocilizumab and sarilumab could help save lives among Covid-19 patients admitted to an intensive care unit (ICU).

The study

Last week, the portal MedRxiv published results of the REMAP-CAP trial, which assessed 803 Covid-19 patients in ICU. Of them, 353 were administered tocilizumab within 24 hours of ICU admission, another 48 were given sarilumab within the same time-frame, and the remaining 402 were administered standard care minus these two drugs (the control arm).

While 64.2% ICU patients survived in the control arm, 72% survived when administered tocilizumab and 77.8% survived when given sarilumab.

The researchers found that the two arthritis drugs, now repurposed for Covid treatment, also helped reduce the need for organ support. Those given tocilizumab required organ support after 10 days on an average, those on sarilumab required after 11 days, and those in the control arm required organ support system in a single day.

What this could mean

This trial shows the drugs cannot be written off so easily, said Dr Shashank R Joshi, who has been part of another study to assess arthritis drug itolizumabs role in Covid-19 treatment. Joshi said despite multiple trial studies yielding unfavourable conclusions for immunosuppressants use against Covid-19, they have found tocilizumab (marketed as Actemra by Roche) effective if used at the correct time. In clinical practice we have observed that if a patient is on high flow nasal cannula and put on steroids, and if his condition deteriorates within next 24 hours in ICU, an immunosuppressant drug can be the correct intervention at that point. We have seen several patients turn around towards recovery, Joshi said.

In India, three immunosuppressant drugs tocilizumab, sarilumab, and itolizumab are used to treat rheumatoid arthritis. These drugs work against a protein called IL-6, which plays a key role in the body mounting a cytokine response (when the immune system attacks the bodys own cells) after the virus infects the body. By suppressing IL-6, these repurposed drugs are supposed to stop the self-damaging cytokine response in severe Covid-19 infections.

Red flags

The Indian Council of Medical Research has previously warned against indiscriminate use of drugs such as remdesivir and tocilizumab in Covid-19 patients as they can do more harm than good. Four months before the UK approved use of the arthritis drugs, Maharashtra had removed tocilizumab from its Covid-19 treatment protocol. Several trials and studies had led to this decision. The most crucial one came from tocilizumab manufacturer Roche in July 2020: it published phase-III trial results that found tocilizumab did not meet the primary endpoint of clinical improvement or the secondary endpoint of reduction in mortality.

In October 2020, the New England Journal of Medicine published a study on 243 patients that found tocilizumab was not effective in preventing death in moderately ill, hospitalised Covid-19 patients.

In September 2020, pharma giant Sanofi halted its trial on sarilumab stating it did not work against Covid-19 after testing it on 420 patients. That July, Sanofi had halted a similar trial in the US after assessing 194 patients. In fact, Sanofi had said sarilumab was associated with a 3% higher risk of adverse events in comparison to the placebo group.

Unsettled debate

Why are the latest findings so contradictory? Intensivist Dr Rahul Pandit, who was himself treated with tocilizumab for Covid-19 last year, said he has completely stopped use of the drug. We cannot rush into a conclusion with this one new research. We need to look at bigger data, Pandit said.

Pandit stopped use of tocilizumab and itolizumab five months ago. There was no evidence of improvement or reduction in mortality. Patients are at risk of secondary infection with this drug, he said.

But as Dr Joshi puts it, Each clinical trial has a different yardstick to measure the endpoint. This is only a year-old illness. We need to wait for more data before writing off drugs.

See original here:
Now out of favour, now back: arthritis drugs in Covid-19 treatment - The Indian Express

About 374,000 Canadians live with rheumatoid arthritis which affects their joins and puts them at higher risk for other health problems. (ljubaphoto/iStock)

People who have been diagnosed with rheumatoid arthritis have an increased risk of cardiovascular disease and infection. Researchers at Arthritis Research Canada have found that they also have a higher risk of developing life threatening blood clots.

Rheumatoid arthritis (RA) occurs when the bodys immune system mistakenly attacks the lining of the joints and other tissues causing swelling, pain, and stiffness. It can affect almost all organ systems and cause such things as cardiovascular problems, infections, depression and gastrointestinal ulcers. About 1.2 per cent of Canadian aged 16 and older live with the condition. It affects more women than men.

For this study, the researchers investigated the risk of blood clots that start in a vein and can travel to the lungs and blood clots in veins of the leg. These kinds of clots (VTE) affect more than one in 1,000 people in Western populations each year.

Dr. Antonio Avia-Zubieta says the higher risk of blood clots must be taken into account in treating patients diagnosed with rheumatoid arthritis. (Sombilon Studios)

The study found that the risk of VTE was highest in the first year after patients are diagnosed with rheumatoid arthritis. The risk decreases progressively as patients are treated for the inflammation associated with arthritis but it is still significantly higher five years later.

These findings have important implications for clinical care, both immediately after a rheumatoid arthritis diagnosis and in long-term treatment as treating inflammation decreases the risk, said Antonio Avia-Zubieta, a rheumatologist and senior scientist of rheumatology at Arthritis Research Canada. Clinicians should be aware that RA causes patients to have a higher risk not only of heart attacks and strokes, but also VTE, particularly in the period soon after diagnosis.

The study was published in the journal Rheumatology.

Arthritis Research Canada is the largest clinical research institution in North America.

Read the original here:
Rheumatoid arthritis patients at higher risk of dangerous blood clots: study - Radio Canada International - English Section

The Global Rheumatoid Arthritis Treatment Market report provides a holistic evaluation of the market for the forecast period (20192025). The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics involve the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Rheumatoid Arthritis Treatment Market study provides an outlook on the development of the market in terms of revenue throughout the prognosis period.

In order to present an executive-level model of the market and its future perspectives, the Rheumatoid Arthritis Treatment Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally).

Major Players included in this report are as follows Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/166

Rheumatoid Arthritis Treatment Market: Regional analysis includes:

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Rheumatoid Arthritis Treatment Market.

Rheumatoid Arthritis Treatment Market scope

A basic summary of the competitive landscape A detailed breakdown of the regional expanse A short overview of the segmentation

Furthermore, this study will help our clients solve the following issues:

Cyclical dynamics We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and disruptions.

Identifying key cannibalizes Strong substitute of a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance.

Spotting emerging trends Our Ecosystem offering helps the client to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have an early mover advantage.

Interrelated opportunities This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/166

Some of the Major Highlights of TOC covers:

Rheumatoid Arthritis Treatment Regional Market Analysis

Rheumatoid Arthritis Treatment Production by Regions Global Rheumatoid Arthritis Treatment Production by Regions Global Rheumatoid Arthritis Treatment Revenue by Regions Rheumatoid Arthritis Treatment Consumption by Regions

Rheumatoid Arthritis Treatment Segment Market Analysis (by Type)

Global Rheumatoid Arthritis Treatment Production by Type Global Rheumatoid Arthritis Treatment Revenue by Type Rheumatoid Arthritis Treatment Price by Type

Rheumatoid Arthritis Treatment Segment Market Analysis (by Application)

Global Rheumatoid Arthritis Treatment Consumption by Application Global Rheumatoid Arthritis Treatment Consumption Market Share by Application (2014-2019)

Rheumatoid Arthritis Treatment Major Manufacturers Analysis

Rheumatoid Arthritis Treatment Production Sites and Area Served Product Introduction, Application and Specification Rheumatoid Arthritis Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)Main Business and Markets Served

Key questions answered in the report:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/166

Key Benefits

Major countries in each region are mapped according to individual market revenue. Comprehensive analysis of factors that drive and restrict market growth is provided. The report includes an in-depth analysis of current research and clinical developments within the market. Key players and their key developments in recent years are listed.And More.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

Excerpt from:
Rheumatoid Arthritis Treatment Market With Focus On Growth Analysis, Production, Consumption, Revenue, Analysis By 2026 | Pfizer, Inc., Johnson &...

Rheumatoid arthritis and pregnancy: Heres what women with RA need to know  |  Photo Credit: iStock Images

New Delhi: Pregnancy is a beautiful phase in a womans life. But what if you have a condition like rheumatoid arthritis (RA), you may have a number of questions, including how it will affect your pregnancy and the babys development. And theres another vital question - will I be able to care for my new baby.

If you have rheumatoid arthritis and are pregnant or planning to become pregnant, its important to know how RA and pregnancy can affect each other. Rheumatoid arthritis is a chronic inflammatory disorder that affects many joints, including those in the hands and feet. It may strike women in their mid-twenties and early 30s, aprimary time period when a woman plans her pregnancy. In this article, Dr Singhai Shweta, consultant - rheumatology- Sakra World Hospital, Bengaluru, tells us how rheumatoid arthritis could affect pregnancy and what women can do to manage their condition, which will enable them a healthy pregnancy and a healthy baby.

It has been observed that most pregnant women with RA have low disease activity during pregnancy and may get remission by the third trimester. However, among few women with severe disease activity, the condition can lead to several complications like preterm birth, raised blood pressure or preeclampsia, low birth weight babies and increased possibility of C-section delivery. Thus, those with controlled RA certainly have healthier pregnancies and babies than those with worse disease activity.

Rheumatoid arthritis may cause low birth weight babies. Also, about 3 per cent to 5 per cent of newborns to mothers with acute RA may have birth defects. This happens due to certain antirheumatic drugs that may mess up with the foetal formation. This is why a woman with RA must essentially consult a doctor before planning a pregnancy.

Things a pregnant mom with RA must keep in mind:

A majority of pregnant women, as much as 60 per cent, experience improvement in their symptoms due to a number of reasons, such as:

Managing rheumatoid arthritis is extremely essential for a healthy pregnancy and a healthy baby. Heres what women can do to manage RA effectively:

Also, stay away from foods that may cause a flare-up: Identify the foods that may worsen the condition and avoid them to prevent a flare-up.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read this article:
Rheumatoid arthritis and pregnancy: Heres what women with RA need to know - Times Now